Blood tests could predict melanoma treatment success

NCT ID NCT07584291

Recruiting now Knowledge-focused Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study enrolls 200 people with acral or cutaneous melanoma who are starting standard immunotherapy. Researchers will collect blood samples every 3 weeks and tumor tissue after about 3 months of treatment. By analyzing circulating tumor cells, DNA, and other markers, they aim to develop a model that predicts how well a patient responds to therapy. The goal is to enable personalized monitoring and treatment strategies for melanoma.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acral lentiginous melanoma cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA (SKIN CANCER)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Xijing Hospital, Air Force Medical University
RECRUITING

Xi'an, Shaanxi, China

Contact Phone: •••-•••-•••• Email: •••••@•••••